Science

Pfizer begins study of mRNA flu vaccine

The Pfizer logo

The Pfizer logo

Pfizer Inc said on Monday it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker and BioNTech.

The early-stage trial, conducted in the United States, will test the vaccine in healthy adults ages 65- 85.

"The COVID-19 pandemic allowed us to deliver on the immense scientific opportunity of mRNA. Influenza remains an area where we see a need for vaccines," said Kathrin Jansen, head of vaccine research and development at Pfizer.

The study will test the safety and immune responses of the vaccine, compared to another FDA-approved influenza vaccine.


Our code of editorial values

Related Topics
This article is closed for comments.
Please Email the Editor

Printable version | Jun 24, 2022 8:23:06 am | https://www.thehindu.com/sci-tech/science/pfizer-begins-study-of-mrna-flu-vaccine/article36705770.ece